Beyond BRCA1/2: Clinician-reported utility 3 years post panel testing.

e18705Background: Germlinetesting guidelines are centered on BRCA1 and BRCA2 despite clear medical management recommendations in several other high and moderate penetrance genes. Clinician utiliza...